Pankaj Yadav
Department of Pharmaceutics, College of Pharmacy, Lords University, Chikani, Alwar, Bhiwadi Rd, Chikani, Rajasthan 301028, India
Abstract
Epilepsy is a brain disease characterized by abnormal electrical activity causing seizures or unusual behavior, sensations and sometimes loss of awareness. An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Pregabalin is an antiepileptic drug belonging to BCS class 1 drugs i.e., having high solubility and high permeability. However, its delayed transport across BBB limits its use in emergency situations. The present work was performed to develop BSA nanoparticles of pregabalin coated with polysorbate 80. The selected formulation DP 1:2 was evaluated for particle size, zeta potential and surface morphology. The in vitro drug release study revealed that DP 1:2 showed maximum drug release as compared to other batches. The in vivo biodistribution study was performed in wistar rats, using two groups i.e pure drug and DP 1:2 formulation. It was observed from results that PS 80 coated BSA Nanoparticles showed maximum amount of drug reaches in brain in comparison to pure drug. Thus, from the results it was concluded that albumin nanoparticles coated with polysorbate 80 could efficiently target the drug pregabalin into brain.
Keywords: Epilepsy, nanoparticles, blood brain barrier, brain targeting, Bovine serum albumin, Polysorbate 80
